



Pfizer Declares First-Quarter 2017 Dividend

Tuesday, December 13, 2016 - 06:53am

Board of Directors approves increase in quarterly cash dividend to \$0.32 per share

The board of directors of Pfizer Inc. today declared a 32-cent first-quarter 2017 dividend on the company's common stock, payable March 1, 2017, to shareholders of record at the close of business on February 3, 2017. Pfizer increased the dividend by approximately 7 percent, to 32 cents from 30 cents per share.

The first-quarter 2017 cash dividend will be the 313th consecutive quarterly dividend paid by Pfizer.

"The dividend increase demonstrates our continued commitment to deliver value to our shareholders and our confidence in the business," stated Ian Read, Pfizer chairman and chief executive officer. "We remain focused on maximizing total shareholder return, and the dividend is a key component."

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at

[Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

Media: Joan Campion, 212-733-2798 or Investors: Ryan Crowe, 212-733-8160